CN102532271B - Brucella B cell epitope and monoclonal antibody and application thereof - Google Patents
Brucella B cell epitope and monoclonal antibody and application thereof Download PDFInfo
- Publication number
- CN102532271B CN102532271B CN 201110417613 CN201110417613A CN102532271B CN 102532271 B CN102532271 B CN 102532271B CN 201110417613 CN201110417613 CN 201110417613 CN 201110417613 A CN201110417613 A CN 201110417613A CN 102532271 B CN102532271 B CN 102532271B
- Authority
- CN
- China
- Prior art keywords
- ala
- asn
- brucella
- leu
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a Brucella B cell epitope and a monoclonal antibody and application thereof. The sequence of the epitope is DRDLQTGGI. The Brucella B cell epitope of the invention is the core epitope of bp26 protein, in a vaccine strain, and the mutant bp26 protein obtained by mutation of this fragment of sequence cannot induce generation of antibodies against the epitope after being immunized in goat, so as to achieve differential diagnosis of natural infection and vaccine inoculation immunization.
Description
Technical field
The present invention relates to a kind of brucella B cell epitope, and use this epi-position to stimulate the anti-brucella bp26 protein monoclonal antibody that obtains.The invention still further relates to the application of this cell epitope antibody and this cell epitope.
Background technology
Brucellosis (Brucellosis) is present one of the widest popular infectious diseases common to human beings and animals in the world, in recent ten years, and the generation of this disease and popular worldwide in rising trend.Show according to World Health Organization's statistics, the annual 500000 routine people's brucellosis that occur in the whole world, the financial loss that causes every year reaches 3,000,000,000 dollars, the popular polyinfection based on sheep kind Brucella of China's cloth disease, the sheep kind accounts for 80% of epidemic strain.
Brucellosis lacks special effective treatment means at present, and is still limited even heavy dose of antibiotic long-term treatment is produced effects, and especially is difficult to overcome the resistant strains problem, and vaccine inoculation and removing infection host are the main means of prevention and control.The immunological reagent of brucellosis is of a great variety, mainly comprises the inferior anti-unique vaccine of the Yi Miao ﹑ of unit of weak malicious Huo Yi Miao ﹑ Si Yi Miao ﹑ and dna vaccination etc.
Because hot inactivated bacteria lacks active antigenic stimulation, can not bring out detectable IL-12 in vivo, and suppress the generation of IL-12, immune effect is not good, and the dead bacterium humoral immunoresponse(HI) that is mostly unprotect power of bringing out.Though and subunit vaccine can play the provide protection of short-term, can not bring out effective permanent immunity, have only viable bacteria just can bring out cellular immunization.
China comes immune sheep with weak toadstool seedling strain M5-90.It has good immune protective effect to the sheep that grows up, but can cause pregnant sheep miscarriage.Bp26 albumen is relevant with weak toadstool seedling strain virulence, and contains protective epitope, if the bp26 gene that the M5-90 vaccine strain is carried all knocks out, then influences the immune effect of weak toadstool seedling strain.In addition, because the existing diagnostic method of the animal of the animal of M5-90 immunity and wild toxic bacterial strain natural infection can not differentiate that the check and the vaccine immunity that have had a strong impact on brucellosis prevent.Therefore, modify or transform marker vaccine at the epitope of bp26 albumen, can set up this epitope polypeptide ELISA diagnostic method and diagnostic reagent thereof, and then solve the technical barrier of brucellosis differential diagnosis and the weak toadstool seedling strain of genetically engineered mark.
Epi-position research about bp26 albumen, people such as Patricia Seco-Mediavilla have made up serial brachymemma polypeptide expression plasmid, and expression and purification fusion rotein antagonism bp26 monoclonal antibody is carried out epi-position screening, still the epitope section that screens and indeterminate.(referring to Epitope Mapping of the Brucella melitensis BP26 Immunogenic Protein:Usefulness for Diagnosis of Sheep Brucellosis, Seco-Mediavilla, Verger et al. Clin. Vaccine. Immunol. 2003,10 (4): 647).
Summary of the invention
One object of the present invention is to provide a kind of brucella B cell epitope.
Another object of the present invention is to provide the application of above-mentioned B cell epitope in preparation diagnosis, prevention or treatment brucellosis diagnostic reagent or medicine.
Another purpose of the present invention is to provide by above-mentioned cell epitope stimulates the monoclonal antibody that produces.
A further object of the present invention is to provide the application of said monoclonal antibody in preparation diagnosis, prevention or treatment brucellosis diagnostic reagent or medicine.
The technical solution used in the present invention is:
Brucella B cell epitope, its sequence are DRDLQTGGI (SEQ ID NO:1).
The monoclonal antibody of anti-brucella bp26 albumen, its preparation method is:
1) with above-mentioned brucella B cell epitope immune animal;
2) animal splenocyte and the oncocyte fusion of immunity of learning from else's experience, but the hybridoma of the anti-brucella bp26 of stably excreting albumen obtained;
3) collect, the monoclonal antibody of purifying hybridoma secretion, be the monoclonal antibody of anti-brucella bp26 albumen.
Preferably, the serum indirect ELISA titer that produces immunoreactive animal is not less than 1:51200.
The invention has the beneficial effects as follows:
Brucella B cell epitope of the present invention, core epi-position for bp26 albumen, the sudden change bp26 albumen that obtains behind this section series jump in the vaccine strain can't be induced the antibody that produces anti-this epi-position after immune sheep, thereby reaches the differential diagnosis of natural infection and vaccine inoculation immunity.
Brucella B cell epitope of the present invention can be used for detecting the brucellosis in the sheep blood serum after the coupling, sets up the Peptide-ELISA detection method, for the development of novel molecular marker vaccine provides foundation.
Monoclonal antibody of the present invention has the excellent specificity recognition capability to bp26 albumen, can accurately identify brucellar epi-position.
Monoclonal antibody of the present invention and B cell epitope are used for the diagnosis of brucellosis, can identify animal well and be natural infection cloth disease or immunoprophylaxis.
Description of drawings
Fig. 1 is recombinant protein bp26 expression and purification electrophoresis evaluation figure;
Fig. 2 is the reactive result that the Western-Blot test detects the natural membranes albumen that extracts among monoclonal antibody bp26-3H5 and the brucella vaccine strain M5-90;
Fig. 3 is peptide matrix design preliminary screening bp26-3H5 epitope;
Fig. 4 is that competition suppresses ELISA mensuration monoclonal antibody strain bp26-3H5 epitope;
Fig. 5 is antigen epitope polypeptide and mutant peptide and monoclonal antibody bp26-3H5 reaction.
Embodiment
Below in conjunction with embodiment, further specify the present invention.
The brucella M5-90 vaccine strain that the present invention uses is the known vaccine strain of the industry available from the Lanzhou veterinary institute.
The preparation of brucella reorganization membranin bp26
Recombinant plasmid pET-28a-bp26(Xinjiang professor Chen Chuanfu of Shihezi Univ who makes up is so kind as to give) transformed competence colibacillus BL21.The bacterium of will recombinating shakes to the logarithmic growth after date, adds with final concentration 1mM IPTG and induces target protein to express.Induce the back ultrasonication, through identifying that target protein mainly is in the precipitation.With inclusion body with the inclusion body washings of 5M urea concentration (1 * PBS, the 5M urea, 1% TritonX-100,1mmol/L EDTA, pH8.0) after the washing, target protein purity reaches more than 85%.With the precipitation after the washing with the 6M Guanidinium hydrochloride (1 * PBS, 6M Guanidinium hydrochloride pH8.0) carry out gradient dialysis renaturation after the dissolving, after the renaturation albumen concentrated and measures protein concentration (see accompanying drawing 1, among the figure, M: marker; 1: full bacterium before inducing; 2: induce the full bacterium in back; 3: ultrasonic back supernatant; 4: ultrasonic postprecipitation; 5: inclusion body washing and renaturation concentrate).
Certainly, also can use the brucella reorganization membranin bp26 that additive method prepares, or directly buy the brucella reorganization membranin bp26 of purifying.
The monoclonal antibody of preparation reorganization membranin bp26
1. mouse immune
1) select the female BALB/c mouse of pure lines in 6 ages in week, with the reorganization bp26 albumen of purifying as the immunizing antigen immune mouse, after bp26 albumen and isopyknic Freund's complete adjuvant (CFA) emulsification, the subcutaneous multi-point injection in back or abdominal cavity;
2) behind the initial immunity behind the bp26 and isopyknic Freund's incomplete adjuvant (IFA) emulsification of 2 weeks with purifying, the subcutaneous multi-point injection in back or abdominal cavity;
3) after 2 weeks, mouse tail is got blood, and centrifugal acquisition serum adopts indirect-ELISA method to survey the serum doubling dilution and tires, and tiring to be not less than 1:51200;
4) merge first three day, abdominal injection bp26 albumen;
The amount of three immunizing antigens is respectively 100 μ g/ mouse, 50 μ g/ mouse, 50 μ g/ mouse.
2. cytogamy
Disconnected neck is put to death the good BALB/c mouse of above-mentioned immunity, and splenocyte and the SP2/0 murine myeloma cell of getting immune mouse merge under 50% PEG4000 fusogen by 5:1, merges the back and selects the substratum bed board to place 37 ℃ of 5%CO with HAT
2Cultivate.
3. positive colony screens and the clone
Utilize the reorganization bp26 albumen of purifying with the strain of indirect ELISA method screening positive hybridoma cell, after the enlarged culturing of positive hole, carry out cell clone with limiting dilution assay, obtain the monoclonal antibody specific cell strain bp26-3H5 that 1 strain can be stablized the anti-bp26 albumen of the justacrine that goes down to posterity through three time clonings.
The evaluation of monoclonal antibody
1. the subgroup identification of monoclonal antibody
With reference to Hycult Biotechnol company mouse source antibody typing test kit specification sheets hybridoma bp26-3H5 being identified, is IgG2b through identifying the bp26-3H5 heavy chain, and light chain is the κ chain.
2. Western-Blot identifies
Press the Bio-rad membranin and extract test kit specification sheets extraction brucella M5-90 vaccine strain membranin, extract the back membranin and press 1:1 adding 2 * SDS sample-loading buffer, boil 5min in the boiling water bath, the centrifugal 1min of 12000rpm gets supernatant 10 μ l and carries out separation gel 12%, concentrate the SDS-PAGE electrophoretic separation of glue 5%, electrotransfer is to pvdf membrane, and pvdf membrane is hatched 1h with the cell conditioned medium 1:3 dilution of each strain monoclonal antibody subsequently to contain 5% skim-milk TBST sealing 2h, TBST washes film three times, each 10min; The Yang KangshuIgG ﹠amp of horseradish peroxidase-labeled; IgM is as the two anti-1h of hatching, and TBST washes luminous development behind the film.
In the test with the strain monoclonal antibody of HCV NS3 as negative control.
Test-results shows that bp26-3H5 and natural membranes albumen have an obvious band being about the 28KDa place, and the monoclonal antibody of negative control HCV NS3 does not react (Fig. 2) with membranin.
Peptide matrix design preliminary screening bp26-3H5 epitope
According to pET-28a-bp26 sequencing result (seeing the sequence shown in SEQ ID NO:4 and the SEQ ID NO:5), 28 overlapping peptides have been designed and synthesized, 10 ~ 16 amino acid of length, overlapping 7 amino acid between per two polypeptide (epi-position that comprises all≤8 amino-acid residues) (table 1).Polypeptide is divided into 11 peptide ponds (seeing Table 2), every polypeptide final concentration 5 μ g/ml in the peptide pond, every hole 100 μ l bag is spent the night; After the washings PBST washing 4 times, with PBS+4%BSA, 37 ℃ of sealings of every hole 200 μ l one hour; After the washings washing 4 times, be that primary antibodie is hatched 45min for 37 ℃ with each monoclonal antibody strain cell conditioned medium of 50 μ l+50 μ l antibody diluents (PBST+1%BSA); After the washings washing 6 times, the HRP mark sheep anti-mouse igg+IgM of 1:10000 antibody diluent dilution is two anti-, and every hole 100 μ l are hatched 30min for 37 ℃; After the washings washing 6 times, add TMB-H
2O
2, every hole 100 μ l lucifuges colour developing 10min, every hole 50 μ l 2M H
2SO
4Termination reaction.Measure the optical density(OD) (OD) in every hole under the 450nm wavelength.As positive control, negative control is serum before the mouse immune with serum behind the mouse immune bp26 albumen.To treat that gaging hole OD450nm 〉=2.1 a times negative control OD450nm is judged to the positive.Through measuring two peptide pond reactions of monoclonal antibody bp26-3H5 and POOLX2 and POOLY5 (Fig. 3), so the polypeptide that bp26-3H5 reacts is the polypeptide P11 that two peptide ponds intersect.
Competition suppresses the B cell epitope that monoclonal antibody bp26-3H5 is accurately measured in the ELISA test
The bp26-3H5 epitope that screening obtains according to above-mentioned peptide matrix as can be known, monoclonal antibody bp26-3H5 can react with P11, so P11 is spent the night for 4 ℃ by 96 orifice plates with 5 μ g/ml bag, behind PBS+4%BSA sealing 1h, with six 9 peptide P1101 ~ P1106s (final concentration 0 μ g/ml, the 1 μ g/ml of 50 μ l cell conditioned mediums+50 μ l with correspondence, 2 μ g/ml, 4 μ g/ml, 8 μ g/ml, 16 μ g/ml) inhibition is at war with.As positive control, wherein 16 peptides of HCV NS3 are as negative control with P11.The equal value representation of the OD450nm in the two multiple holes of measuring result.
P1104 DRDLQTGGI 93 ~ 101 suppresses the ELISA test through competition and obtains following result: P1104 and positive control P11 and can effectively suppress mAb BP26-3H5 and be combined with P11, so may be bp26-3H5 monoclonal antibody minimum epitope motif (Fig. 4).
The mutation analysis of epitope core sequence
Bp26-3H5 epitope according to accurate mensuration, its nucleus is DRDLQTGGI(93 ~ 101) the 93rd and 95 aspartic acid among the P11 is sported l-asparagine become MutP11, its aminoacid sequence is the sequence KKAGIENRNLQTGGIN shown in the SEQ ID NO:3.Method with Peptide-ELISA, with P11, MutP11 reacts with monoclonal antibody bp26-3H5 respectively, and its result shows that the polypeptide (MutP11) after the sudden change descends than sudden change epitope peptide (P11) significant reaction before, further confirms to comprise among the P11 B cell epitope (Fig. 5) of bp26.
Epitope polypeptide detects sheep blood serum
After polypeptide P11 and hemocyanin (KLH) coupling, spent the night 60 parts of immunity or infect sheep blood serum as primary antibodie, the anti-sheep IgG of HRP-rabbit ﹠amp with described 5 μ g/ml bag before; IgM is two anti-.41 parts of seropositivities after measured, recall rate 68.3%.
＜110〉Nanfang Medical Univ
＜120〉a kind of brucella B cell epitope and monoclonal antibody and application
<130>
<160> 37
<170> PatentIn version 3.5
<210> 1
<211> 9
<212> PRT
<213> Brucella melitensis
<400> 1
Asp Arg Asp Leu Gln Thr Gly Gly Ile
1 5
<210> 2
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 2
Lys Lys Ala Gly Ile Glu Asn Arg Asn Leu Gln Thr Gly Gly Ile Asn
1 5 10 15
<210> 3
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 3
Lys Lys Ala Gly Ile Glu Asn Arg Asn Leu Gln Thr Gly Gly Ile Asn
1 5 10 15
<210> 4
<211> 753
<212> DNA
<213> Brucella melitensis
<400> 4
atgaacactc gtgctagcaa ttttctcgca gcctcatttt ccacaatcat gctcgtcggc 60
gctttcagcc tgcccgcttt cgcacaggag aatcagatga cgacgcagcc cgcgcgcatc 120
gccgtcaccg gggaaggcat gatgacggcc tcgcccgata tggccattct caatctctcg 180
gtgctacgcc aggcaaagac cgcgcgcgaa gccatgaccg cgaataatga agccatgaca 240
aaagtgctcg atgccatgaa gaaggccggc atcgaagatc gcgatctcca gacaggcggc 300
atcaatatcc agccgattta tgtctatcct gacgacaaga acaacctgaa agagcctacc 360
atcaccggct attctgtatc caccagtctc acggttcgcg tgcgcgaact ggccaatgtt 420
ggaaaaattt tggatgaatc cgtcacgctc ggtgttaatc agggcggtga tttgaacctg 480
gtcaatgata atccctccgc cgtgatcaac gaggcgcgca agcgcgcagt ggccaatgcc 540
attgccaagg cgaagacgct tgccgacgct gcaggcgtgg ggcttggccg tgtggtggaa 600
atcagtgaac tgagccgccc gcccatgccg atgccaattg cgcgcggaca gttcagaacc 660
atgctagcag ccgcaccgga caattccgtg ccgattgccg caggcgaaaa cagctataac 720
gtatcggtca atgtcgtttt tgaaatcaag taa 753
<210> 5
<211> 250
<212> PRT
<213> Brucella melitensis
<400> 5
Met Asn Thr Arg Ala Ser Asn Phe Leu Ala Ala Ser Phe Ser Thr Ile
1 5 10 15
Met Leu Val Gly Ala Phe Ser Leu Pro Ala Phe Ala Gln Glu Asn Gln
20 25 30
Met Thr Thr Gln Pro Ala Arg Ile Ala Val Thr Gly Glu Gly Met Met
35 40 45
Thr Ala Ser Pro Asp Met Ala Ile Leu Asn Leu Ser Val Leu Arg Gln
50 55 60
Ala Lys Thr Ala Arg Glu Ala Met Thr Ala Asn Asn Glu Ala Met Thr
65 70 75 80
Lys Val Leu Asp Ala Met Lys Lys Ala Gly Ile Glu Asp Arg Asp Leu
85 90 95
Gln Thr Gly Gly Ile Asn Ile Gln Pro Ile Tyr Val Tyr Pro Asp Asp
100 105 110
Lys Asn Asn Leu Lys Glu Pro Thr Ile Thr Gly Tyr Ser Val Ser Thr
115 120 125
Ser Leu Thr Val Arg Val Arg Glu Leu Ala Asn Val Gly Lys Ile Leu
130 135 140
Asp Glu Ser Val Thr Leu Gly Val Asn Gln Gly Gly Asp Leu Asn Leu
145 150 155 160
Val Asn Asp Asn Pro Ser Ala Val Ile Asn Glu Ala Arg Lys Arg Ala
165 170 175
Val Ala Asn Ala Ile Ala Lys Ala Lys Thr Leu Ala Asp Ala Ala Gly
180 185 190
Val Gly Leu Gly Arg Val Val Glu Ile Ser Glu Leu Ser Arg Pro Pro
195 200 205
Met Pro Met Pro Ile Ala Arg Gly Gln Phe Arg Thr Met Leu Ala Ala
210 215 220
Ala Pro Asp Asn Ser Val Pro Ile Ala Ala Gly Glu Asn Ser Tyr Asn
225 230 235 240
Val Ser Val Asn Val Val Phe Glu Ile Lys
245 250
<210> 6
<211> 12
<212> PRT
<213> Brucella melitensis
<400> 6
Met Asn Thr Arg Ala Ser Asn Phe Leu Ala Ala Ser
1 5 10
<210> 7
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 7
Ser Asn Phe Leu Ala Ala Ser Phe Ser Thr Ile Met Leu Val Gly Ala
1 5 10 15
<210> 8
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 8
Thr Ile Met Leu Val Gly Ala Phe Ser Leu Pro Ala Phe Ala Gln Glu
1 5 10 15
<210> 9
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 9
Leu Pro Ala Phe Ala Gln Glu Asn Gln Met Thr Thr Gln Pro Ala Arg
1 5 10 15
<210> 10
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 10
Met Thr Thr Gln Pro Ala Arg Ile Ala Val Thr Gly Glu Gly Met Met
1 5 10 15
<210> 11
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 11
Val Thr Gly Glu Gly Met Met Thr Ala Ser Pro Asp Met Ala Ile Leu
1 5 10 15
<210> 12
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 12
Ser Pro Asp Met Ala Ile Leu Asn Leu Ser Val Leu Arg Gln Ala Lys
1 5 10 15
<210> 13
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 13
Ser Val Leu Arg Gln Ala Lys Thr Ala Arg Glu Ala Met Thr Ala Asn
1 5 10 15
<210> 14
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 14
Arg Glu Ala Met Thr Ala Asn Asn Glu Ala Met Thr Lys Val Leu Asp
1 5 10 15
<210> 15
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 15
Ala Met Thr Lys Val Leu Asp Ala Met Lys Lys Ala Gly Ile Glu Asp
1 5 10 15
<210> 16
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 16
Leu Gln Thr Gly Gly Ile Asn Ile Gln Pro Ile Tyr Val Tyr Pro Asp
1 5 10 15
<210> 17
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 17
Pro Ile Tyr Val Tyr Pro Asp Asp Lys Asn Asn Leu Lys Glu Pro Thr
1 5 10 15
<210> 18
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 18
Asn Asn Leu Lys Glu Pro Thr Ile Thr Gly Tyr Ser Val Ser Thr Ser
1 5 10 15
<210> 19
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 19
Gly Tyr Ser Val Ser Thr Ser Leu Thr Val Arg Val Arg Glu Leu Ala
1 5 10 15
<210> 20
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 20
Val Arg Val Arg Glu Leu Ala Asn Val Gly Lys Ile Leu Asp Glu Ser
1 5 10 15
<210> 21
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 21
Gly Lys Ile Leu Asp Glu Ser Val Thr Leu Gly Val Asn Gln Gly Gly
1 5 10 15
<210> 22
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 22
Leu Gly Val Asn Gln Gly Gly Asp Leu Asn Leu Val Asn Asp Asn Pro
1 5 10 15
<210> 23
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 23
Asn Leu Val Asn Asp Asn Pro Ser Ala Val Ile Asn Glu Ala Arg Lys
1 5 10 15
<210> 24
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 24
Val Ile Asn Glu Ala Arg Lys Arg Ala Val Ala Asn Ala Ile Ala Lys
1 5 10 15
<210> 25
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 25
Val Ala Asn Ala Ile Ala Lys Ala Lys Thr Leu Ala Asp Ala Ala Gly
1 5 10 15
<210> 26
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 26
Thr Leu Ala Asp Ala Ala Gly Val Gly Leu Gly Arg Val Val Glu Ile
1 5 10 15
<210> 27
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 27
Leu Gly Arg Val Val Glu Ile Ser Glu Leu Ser Arg Pro Pro Met Pro
1 5 10 15
<210> 28
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 28
Leu Ser Arg Pro Pro Met Pro Met Pro Ile Ala Arg Gly Gln Phe Arg
1 5 10 15
<210> 29
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 29
Ile Ala Arg Gly Gln Phe Arg Thr Met Leu Ala Ala Ala Pro Asp Asn
1 5 10 15
<210> 30
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 30
Leu Ala Ala Ala Pro Asp Asn Ser Val Pro Ile Ala Ala Gly Glu Asn
1 5 10 15
<210> 31
<211> 11
<212> PRT
<213> Brucella melitensis
<400> 31
Pro Ile Ala Ala Gly Glu Asn Ser Tyr Asn Val
1 5 10
<210> 32
<211> 16
<212> PRT
<213> Brucella melitensis
<400> 32
Gly Glu Asn Ser Tyr Asn Val Ser Val Asn Val Val Phe Glu Ile Lys
1 5 10 15
<210> 33
<211> 9
<212> PRT
<213> Brucella melitensis
<400> 33
Gly Ile Glu Asp Arg Asp Leu Gln Thr
1 5
<210> 34
<211> 9
<212> PRT
<213> Brucella melitensis
<400> 34
Ile Glu Asp Arg Asp Leu Gln Thr Gly
1 5
<210> 35
<211> 9
<212> PRT
<213> Brucella melitensis
<400> 35
Glu Asp Arg Asp Leu Gln Thr Gly Gly
1 5
<210> 36
<211> 9
<212> PRT
<213> Brucella melitensis
<400> 36
Arg Asp Leu Gln Thr Gly Gly Ile Asn
1 5
<210> 37
<211> 9
<212> PRT
<213> Brucella melitensis
<400> 37
Asp Leu Gln Thr Gly Gly Ile Asn Ile
1 5
Claims (2)
1. brucella B cell epitope, its sequence is DRDLQTGGI (SEQ ID NO:1).
2. the application of the described brucella B of claim 1 cell epitope in preparation diagnosis brucellosis diagnostic reagent or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110417613 CN102532271B (en) | 2011-12-14 | 2011-12-14 | Brucella B cell epitope and monoclonal antibody and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110417613 CN102532271B (en) | 2011-12-14 | 2011-12-14 | Brucella B cell epitope and monoclonal antibody and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102532271A CN102532271A (en) | 2012-07-04 |
| CN102532271B true CN102532271B (en) | 2013-07-03 |
Family
ID=46340424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110417613 Expired - Fee Related CN102532271B (en) | 2011-12-14 | 2011-12-14 | Brucella B cell epitope and monoclonal antibody and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102532271B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104086628A (en) * | 2014-06-11 | 2014-10-08 | 南方医科大学 | Monoclonal antibody of brucella omp31 protein and application thereof |
| CN105693833B (en) * | 2016-04-16 | 2019-05-17 | 中国农业科学院兰州兽医研究所 | A kind of brucella Omp25 Protein Epitopes polypeptide and its application |
| CN108359009B (en) * | 2017-12-28 | 2021-06-04 | 吉林医药学院 | Brucella single-chain antibody and application thereof |
| CN113913442A (en) * | 2020-07-10 | 2022-01-11 | 内蒙古农业大学 | Brucella protein antigen and prokaryotic expression method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101363859B (en) * | 2008-05-26 | 2013-03-06 | 北京庄笛浩禾生物医学科技有限公司 | Test paper strip for rapidly detecting brucellosis antibody |
-
2011
- 2011-12-14 CN CN 201110417613 patent/CN102532271B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102532271A (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107033250B (en) | Bovine coronavirus recombinant multi-epitope antigen and application thereof | |
| CN102532271B (en) | Brucella B cell epitope and monoclonal antibody and application thereof | |
| CN102432673B (en) | Brucella bp26 protein epitope, monoclonal antibody and application thereof | |
| CN101863963B (en) | Helicobacter pylori antigen epitope polypeptide and application thereof | |
| CN101863964B (en) | Helicobacter pylori urease B antigen epitope polypeptide and application thereof | |
| CN101863965B (en) | Helicobacter pylori urease B antigenic epitope polypeptide and application thereof | |
| CN106632619A (en) | Influenza A virus recombinant protein and preparation of monoclonal antibody thereof | |
| CN104086634A (en) | Brucella omp31 antigenic epitope and monoclonal antibody thereof, and application of brucella omp31 antigenic epitope and monoclonal antibody thereof | |
| CN100537767C (en) | Recombinant expressed and the application of pertussis vaccine protective antigen | |
| CN102558306B (en) | Antigen epitope for preventing and treating trichinosis, composition thereof and application thereof | |
| CN107510841A (en) | Source blocks the vaccine that echinococcosis cause of disease Echinococcus granulosus is propagated | |
| CN104086628A (en) | Monoclonal antibody of brucella omp31 protein and application thereof | |
| CN101921325A (en) | Antigen capable of increasing CD4 + CD25 + Foxp3 + regulatory T cells and application thereof | |
| CN101921337B (en) | Antibody against lactate dehydrogenase of plasmodium vivax, related preparation method, hybridoma cell strain and application | |
| CN112812193A (en) | Recombinant protein vaccine of norovirus GII.4 type and enterovirus 71 type | |
| CN114989295B (en) | anti-MERS-CoV monoclonal antibody and application thereof | |
| CN1952137A (en) | Gene expression product of extro-cellular domain amino end of human thyrotropin receptor, its preparing method and application in enzyme immune technology | |
| CN106399294A (en) | Preparation of monoclonal antibody 7H8 capable of resisting epitope at N terminal of human procalcitonin protein | |
| CN109310747A (en) | Just plus this antigen and its antibody and composition, method and purposes | |
| CN104086629A (en) | Brucella omp31 protein B cell epitope and monoclonal antibody and application thereof | |
| CN103131719B (en) | Taenia multiceps enolase TmENO recombinant protein with immunizing protection | |
| CN110483624A (en) | Borrelia garinii OspA PROTEIN C end peptide fragment and its application | |
| CN102206255B (en) | Sequences of mutants of Tat protein of human immunodeficiency virus type I and use thereof | |
| CN102153644B (en) | Antigenic peptide for dimerization of epidermal growth factor receptor | |
| CN107033224B (en) | A kind of foot and mouth disease virus inactivation antigen purifying method for concentration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130703 Termination date: 20151214 |
|
| EXPY | Termination of patent right or utility model |